|
Abstract:
|
Three recent meta-analyses of dose response data will be summarized. One is based on small-molecule data from a single sponsor (Pfizer), one is based on published industry-wide small-molecule data, and one is based on industry-wide biological molecules. The dosing designs that were utilized are described, along with common patterns of dose response. The analyses demonstrate that a single concise parametric Emax model describes most clinical dose response data well. Implications for design and (Bayesian) parametric analyses will be briefly illustrated using the R package clinDR.
|
